MedPath

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Phase 2
Completed
Conditions
Epilepsy, Partial
Interventions
Registration Number
NCT00152451
Lead Sponsor
UCB S.A. - Pharma Sector
Brief Summary

This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria
  • Males/Females from 18 to 65 years of age (minimum body weight of 40 kg)
  • Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures whether or not secondarily generalized
  • Subjects who have been treated for epilepsy for >=6 months and are currently uncontrolled while being treated with 1-3 concomitant Antiepileptic Drug (AEDs)
  • Female subjects without childbearing potential; Female subjects with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method
Exclusion Criteria
  • Seizures occurring in clusters.
  • Status epilepticus within 6 months of Visit 1
  • History of non-epileptic seizures
  • Subjects on vigabatrin
  • Subjects on felbamate, unless treatment has been continuous for >2 years
  • Ongoing psychiatric disease other than mild controlled disorders.
  • Subjects with clinically significant organ dysfunction
  • Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients
  • Pregnant or lactating women
  • Subjects currently taking levetiracetam (LEV)
  • Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant Antiepileptic Drug (AEDs)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SeletracetamSeletracetam (ucb 44212)Escalating doses twice daily were to be administered.
Primary Outcome Measures
NameTimeMethod
Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration PeriodDuring the Up-titration Period (Week 5 to Week 12), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the up-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial onset seizure frequency from Baseline.

The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Secondary Outcome Measures
NameTimeMethod
Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) Overall in the Up-titration PeriodDuring the Up-Titration Period (Week 5 to Week 12), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the up-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in seizure frequency from Baseline.

The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Up-titration PeriodDuring the Up-Titration Period (Week 5 to Week 12)

Calculated as 7-day partial onset seizure (type I) frequency. The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Overall in the Down-titration PeriodDuring the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the down-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). A negative value in change from Baseline indicates a decrease in partial onset seizure frequency from Baseline. The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I + II + III) Overall in the Down-titration PeriodWeek 13 to Week 15, compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the down-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). A negative value in change from Baseline indicates a decrease in all seizure types frequency from Baseline. The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) by Visit Over the Treatment Period (Up-titration + Down-titration)During the Treatment Period (Week 5 to Week 15), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the Treatment Period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial onset seizure frequency from Baseline.

The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15). Visit x includes the period from the beginning of Visit x-1 up to but not including Visit x.

Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Down-titration PeriodDuring the Down-Titration Period (Week 13 to Week 15)

Calculated as 7-day partial onset seizure (type I) frequency. The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Seizure Frequency Per Week for All Seizure Types (Type I+II+III) by Visit Over the Treatment PeriodDuring the Treatment Period (Week 5 to Week 15)

Calculated as 7-day seizure frequency for all seizure types (type I+II+III). The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15). Visit x includes the period from the beginning of Visit x-1 up to but not including Visit x.

Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit Over the Treatment PeriodDuring the Treatment Period (Week 5 to Week 15)

Calculated as 7-day partial onset seizure (type I) frequency; The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15). Visit x includes the period from the beginning of Visit x-1 up to but not including Visit x.

Responder Rate in Partial Onset Seizures (Type I) Over the Up-titration PeriodWeek 12, compared to Baseline Period (Week 1 to Week 4)

A responder was defined as a subject with a \>= 50% reduction in seizure frequency per week from the Baseline Period (Week 1 to Week 4) to the end of the Up-Titration Period.

Percentage of Participants With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Up-titration PeriodWeek 12, compared to Baseline Period (Week 1 to Week 4)

Categories of percentage change in seizures from Baseline were as following: \< -25%; -25% to \<25%; 25% to \<75%; 75% to \<100%; 100%.

Percentage Change From Baseline in Seizure-free Days Per Week Over the Up-titration PeriodWeek 5 to Week 12, compared to Baseline Period (Week 1 to Week 4)

A day was considered seizure-free, if no seizure was reported during 24 hours.

Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II +III) Overall in the Up-titration PeriodWeek 5 to Week 12, compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the up-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). A negative value in change from Baseline indicates a decrease in all seizure types frequency from Baseline. The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Treatment PeriodDuring the Treatment Period (Week 5 to Week 15)

Calculated as 7-day partial onset seizure (type I) frequency. The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15).

Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit Over the Treatment Period (Up-titration + Down-titration)Week 5 to Week 15, compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the treatment period for visit n) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). The treatment period referred to includes the period from the previous visit n-1 up to but not including the specific visit n. A negative value in change from Baseline indicates a decrease in partial onset seizure frequency from Baseline. The Overall Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15).

Percentage Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Overall in the Down-titration PeriodDuring the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the down-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial onset seizure frequency from Baseline.

The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) During the Up-titration PeriodWeek 5 to Week 12, compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the up-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). A negative value in change from Baseline indicates a decrease in partial onset seizure frequency from Baseline. The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) by Visit Over the Treatment Period (Up-titration + Down-titration)During the Treatment Period (Week 5 to Week 15), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the Treatment Period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in seizure frequency from Baseline.

The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15). Visit x includes the period from the beginning of Visit x-1 up to but not including Visit x.

Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) Overall in the Down-titration PeriodDuring the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the down-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in seizure frequency from Baseline.

The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Treatment PeriodDuring the Treatment Period (Week 5 to Week 15)

Calculated as 7-day seizure frequency for all seizure types (type I+II+III). The Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15).

Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Up-titration PeriodDuring the Up-Titration Period (Week 5 to Week 12)

Calculated as 7-day seizure frequency for all seizure types (type I+II+III). The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).

Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Down-titration PeriodDuring the Down-Titration Period (Week 13 to Week 15)

Calculated as 7-day seizure frequency for all seizure types (type I+II+III). The duration of the Down-Titration Period was 3 weeks (Visit 7/Week 13 to Visit 10/Week 15).

Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) by Visit Over the Treatment Period (Up-titration + Down-titration)Week 5 to Week 15, compared to Baseline Period (Week 1 to Week 4)

Calculated as (7-day seizure frequency during the treatment period for visit n) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)). The treatment period referred to includes the period from the previous visit n-1 up to but not including the specific visit n. A negative value in change from Baseline indicates a decrease in all seizure types frequency from Baseline. The Overall Treatment Period consists of an 8-week Up-Titration Period (Visit 3/Week 5 to Visit 7/Week 12) and a 3-week Down-Titration Period (Visit 7/Week 13 to Visit 10/Week 15).

Trial Locations

Locations (7)

N01191 105

🇺🇸

San Francisco, California, United States

N01191 107

🇺🇸

Columbus, Ohio, United States

N01191 104

🇺🇸

Philadelphia, Pennsylvania, United States

N01191 101

🇺🇸

Nashville, Tennessee, United States

N01191 103

🇺🇸

Charlottesville, Virginia, United States

N01191 102

🇺🇸

Stanford, California, United States

N01191 108

🇺🇸

Little Rock, Arkansas, United States

© Copyright 2025. All Rights Reserved by MedPath